TaiGen

    • Overview
    • Milestones
    • Business Model
    • Steering Committee
    • Board of Directors
    • Management
    • Pipeline
      • Clinical Pipeline
    • Product Overview
      • Nemonoxacin
      • Burixafor
      • Furaprevir
    • Development Projects
      • Nemonoxacin
      • Burixafor
      • Furaprevir
    • Research
      • Influenza Antiviral and Hepatitis B Antiviral
    • News
    • Stakeholders Section
    • Presentation
      • TaiGen Biopharmaceuticals Holdings Investor Meeting (4157 TWO) 20181128
      • TaiGen Biopharmaceuticals Holdings Investor Meeting (4157 TWO) 20171129
      • TaiGen-HEC Newco Analysts Meeting
      • Institutional investors conference on Jul. 06, 2016
      • CLSA China Healthcare-Drug Innovation Forum on Jan. 20-21,2016
      • Morgan Stanley Fourteenth Annual Asia Pacific Summit on Nov. 17-18,2015
    • Shareholders services
      • Shareholders' Meeting
    • Corporate governance
    • Contacts
    • Location
    • Join Us
Home 中文

  • -    Annoucement:TaiGen Has Completed Enrollment for the Phase III Trial of...

    (12/4/2019 )

  • -    Annoucement:Taigexyn IV formulation Pass the Drug Sampling Inspection

    (12/2/2019 )

  • -    Annoucement:Nemonoxacin Oral Formulation Succeeded to Get On Reimburse...

    (11/28/2019 )

  • -    Annoucement:No critical observation in On-site Inspection for NDA Appr...

    (10/29/2019 )

  • -    Announcement: TaiGen submitted Pre-IND meeting of influenza antiviral ...

    (10/21/2019 )

  • Nemonoxacin Broad-spectrum Antibiotic
  • Burixafor Novel Stem Cell Mobilizer
  • Furaprevir Hepatitis C Virus Protease Inhibitor
Copyright © 2014 TaiGen Biotechnology Co., Ltd. Privacy | Terms of use